Chemically stable inhibitors of 14-3-3 protein-protein interactions derived from BV02.


Journal

Journal of enzyme inhibition and medicinal chemistry
ISSN: 1475-6374
Titre abrégé: J Enzyme Inhib Med Chem
Pays: England
ID NLM: 101150203

Informations de publication

Date de publication:
Dec 2019
Historique:
entrez: 8 2 2019
pubmed: 8 2 2019
medline: 23 2 2019
Statut: ppublish

Résumé

14-3-3 are regulatory proteins that through protein-protein interactions (PPI) with numerous binding partners could be involved in several human diseases, including cancer, neurodegenerative disorders, and pathogens infections. Following our research interest in the development of 14-3-3 PPI inhibitors, here we exploited the privileged 4-aminoantipyrine scaffold in the design and synthesis of some derivatives endowed with antiproliferative activity against K-562 cells, and capable of binding to recombinant 14-3-3σ as evidenced by NMR spectroscopy. The binding mode was further explored by molecular modelling, while coupling confocal microscopy with intensitometric analysis showed that compound 1 was able to promote the nuclear translocation of c-Abl at low micromolar concentrations. Overall, 1 is chemically stable compared to parent 14-3-3 PPI inhibitors, and thus emerged as a confirmed hit for further development.

Identifiants

pubmed: 30727786
doi: 10.1080/14756366.2019.1574779
pmc: PMC8853708
doi:

Substances chimiques

14-3-3 Proteins 0
Antineoplastic Agents 0
BV02 compound 0
Benzamides 0
Pyrazoles 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

657-664

Références

ChemMedChem. 2014 May;9(5):973-83
pubmed: 24715717
Annu Rev Biophys Biomol Struct. 2005;34:245-66
pubmed: 15869390
J Mol Biol. 1997 Apr 4;267(3):727-48
pubmed: 9126849
Drug Discov Today Technol. 2013 Dec;10(4):e541-7
pubmed: 24451646
Bioorg Med Chem Lett. 2010 Oct 15;20(20):6133-7
pubmed: 20832303
Proteins. 2003 Sep 1;52(4):609-23
pubmed: 12910460
J Chem Inf Model. 2015 Dec 28;55(12):2611-22
pubmed: 26551337
ACS Chem Biol. 2015 Sep 18;10(9):1964-9
pubmed: 26121309
J Med Chem. 2018 May 10;61(9):3755-3778
pubmed: 28968506
J Biol Chem. 2005 May 13;280(19):18891-8
pubmed: 15731107
Curr Med Chem. 2018;25(1):5-21
pubmed: 28462702
Plant Mol Biol. 2002 Dec;50(6):993-1010
pubmed: 12516867
Molecules. 2018 Jun 08;23(6):
pubmed: 29890630
Int J Cancer. 2008 Jan 15;122(2):289-97
pubmed: 17893873
Bioorg Med Chem Lett. 2011 Nov 15;21(22):6867-71
pubmed: 21962576
Methods Enzymol. 2003;362:417-34
pubmed: 12968380
Proc Natl Acad Sci U S A. 1988 Oct;85(19):7084-8
pubmed: 2902623
J Pharmacol Exp Ther. 2011 Mar;336(3):596-604
pubmed: 21041536
Bioorg Med Chem Lett. 2016 Feb 1;26(3):894-898
pubmed: 26774582

Auteurs

Leire Iralde-Lorente (L)

a Department of Biotechnology, Chemistry and Pharmacy , Università degli Studi di Siena , Siena , Italy.

Ylenia Cau (Y)

a Department of Biotechnology, Chemistry and Pharmacy , Università degli Studi di Siena , Siena , Italy.

Letizia Clementi (L)

b Department of Biotechnological and Applied Clinical Sciences , University of L'Aquila , L'Aquila , Italy.

Lorenzo Franci (L)

c Istituto per lo Studio , la Prevenzione e la Rete Oncologica (ISPRO) , Siena , Italy.
d Department of Medical Biotechnologies , PhD course GenOMeC, Università degli Studi di Siena , Siena , Italy.
e Consiglio Nazionale delle Ricerche , Istituto di Fisiologia Clinica , Siena , Italy.

Giusy Tassone (G)

a Department of Biotechnology, Chemistry and Pharmacy , Università degli Studi di Siena , Siena , Italy.

Daniela Valensin (D)

a Department of Biotechnology, Chemistry and Pharmacy , Università degli Studi di Siena , Siena , Italy.

Mattia Mori (M)

a Department of Biotechnology, Chemistry and Pharmacy , Università degli Studi di Siena , Siena , Italy.

Adriano Angelucci (A)

b Department of Biotechnological and Applied Clinical Sciences , University of L'Aquila , L'Aquila , Italy.

Mario Chiariello (M)

c Istituto per lo Studio , la Prevenzione e la Rete Oncologica (ISPRO) , Siena , Italy.
e Consiglio Nazionale delle Ricerche , Istituto di Fisiologia Clinica , Siena , Italy.

Maurizio Botta (M)

a Department of Biotechnology, Chemistry and Pharmacy , Università degli Studi di Siena , Siena , Italy.
f Center for Biotechnology, College of Science and Technology, Sbarro Institute for Cancer Research and Molecular Medicine , Temple University , Philadelphia , PA, USA.
g Lead Discovery Siena s.r.l. , Siena , Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH